Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284346 | 0.78 | KDM4E (0.40) | KDM4EMEN1NPC1MAPTRAB9A | |
| SCHEMBL57543 | 0.72 | TRPV4 (0.41) | MAPK1MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL10827797 | 0.71 | KDM4E (0.31) | KDM4ESMN1; SMN2 | |
| Methyl Alcohol SCHEMBL2775838 | 0.70 | TRPV4 (0.36) | MAPK1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL20223494 | 0.70 | KDM4E (0.36) | KDM4EMEN1NPC1MAPTRAB9A | |
| SCHEMBL11063464 | 0.70 | TRPV4 (0.30) | — | |
| SCHEMBL3632823 | 0.70 | CA12 (0.41) | MAPK1HTTKDM4EMEN1MAPT | |
| SCHEMBL15426818 | 0.70 | ADORA2A (0.35) | KDM4E | |
| SCHEMBL31612588 | 0.69 | TRPV4 (0.39) | MAPK1MEN1MAPTKMT2ASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL27947136 | 0.69 | TRPV4 (0.39) | MAPK1MEN1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018566-A1 | PALLADIUM(II)-CATALYZED SELECTIVE FLUORINATION OF BENZOIC ACIDS AND DERIVATIVES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018566-A1 | PALLADIUM(II)-CATALYZED SELECTIVE FLUORINATION OF BENZOIC ACIDS AND DERIVATIVES | AHR, DDT, AOC2 | F2 223/4885LMNA 3776/4885MAPK1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.